1 min read
Bristol Myers Squibb and Erasca Arrange Evaluation of Cancer Drug Pair
Erasca will supply ERAS-0015 for the evaluation, which focuses on pancreatic ductal adenocarcinoma.

Bristol Myers Squibb and Erasca have arranged to evaluate a drug combination of navlimetostat with ERAS-0015 for pancreatic ductal adenocarcinoma, the most prevalent pancreatic cancer type.
ERAS-0015 is a pan-RAS molecular glue, and Erasca will supply it for the evaluation. Navlimetostat is the other compound in the combination.